Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Ibrutinib Plus R-CHOP Warrants Investigation for Some DLBCL Subgroups
Key clinical point: Adding ibrutinib to rituximab plus CHOP chemotherapy may benefit patients with MYC-high and BCL2-high-expressing diffuse large B-cell lymphoma.
Major finding: Adding ibrutinib was associated with improved event-free survival in patients with MYC and BCL2 co-expression, but not an improvement in overall survival.
Study details: A phase 3 trial of 838 patients with non-germinal center B-cell-like diffuse large B-cell lymphoma.
Disclosures: Dr. Johnson reported disclosures related to Celgene, Gilead, Novartis, Roche, and other companies.
Citation:
Johnson P et al. ASH 2019, Abstract 354.